- Home
- MGNX vs BEAT Comparison
MGNX vs BEAT Comparison
Compare MGNX & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- BEAT
- Stock Information
- Founded
- MGNX 2000
- BEAT 2015
- Country
- MGNX United States
- BEAT United States
- Employees
- MGNX N/A
- BEAT N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- MGNX Health Care
- BEAT Technology
- Exchange
- MGNX Nasdaq
- BEAT Nasdaq
- Market Cap
- MGNX 70.3M
- BEAT 59.0M
- IPO Year
- MGNX 2013
- BEAT 2021
- Fundamental
- Price
- MGNX $1.43
- BEAT $1.77
- Analyst Decision
- MGNX Hold
- BEAT Buy
- Analyst Count
- MGNX 10
- BEAT 1
- Target Price
- MGNX $6.83
- BEAT $8.00
- AVG Volume (30 Days)
- MGNX 599.1K
- BEAT 53.6K
- Earning Date
- MGNX 05-20-2025
- BEAT 05-13-2025
- Dividend Yield
- MGNX N/A
- BEAT N/A
- EPS Growth
- MGNX N/A
- BEAT N/A
- EPS
- MGNX N/A
- BEAT N/A
- Revenue
- MGNX $149,962,000.00
- BEAT N/A
- Revenue This Year
- MGNX N/A
- BEAT N/A
- Revenue Next Year
- MGNX $80.86
- BEAT N/A
- P/E Ratio
- MGNX N/A
- BEAT N/A
- Revenue Growth
- MGNX 155.26
- BEAT N/A
- 52 Week Low
- MGNX $0.99
- BEAT $1.45
- 52 Week High
- MGNX $14.91
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- MGNX 43.37
- BEAT 47.28
- Support Level
- MGNX $1.54
- BEAT $1.78
- Resistance Level
- MGNX $1.82
- BEAT $1.91
- Average True Range (ATR)
- MGNX 0.15
- BEAT 0.14
- MACD
- MGNX 0.01
- BEAT 0.02
- Stochastic Oscillator
- MGNX 19.79
- BEAT 38.01
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.